Description
MK 2866 (Ostarine) 10 mg Elbrus Pharmaceuticals — ostarine (MK-2866) from Elbrus Pharmaceuticals at 10 mg. Selective androgen receptor modulator — tissue-targeted for muscle and bone. Milder HPTA suppression than anabolic steroids.
Key Benefits
- Most-studied SARM — extensive clinical trial data
- Low suppression at 10–15 mg/day — recovery often possible without PCT
- Cutting recomp compound — lean mass in caloric deficit
- Oral once-daily dosing
- Starting compound for SARM-curious users
- Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 10–25 mg/day for 8 weeks. Women 5–10 mg/day. Single daily dose adequate given long half-life. Cycles 8–12 weeks. Doses above 25 mg/day suppression becomes meaningful.
How It Works
MK-2866, selective androgen receptor modulator. Binds the AR with tissue selectivity: high activity in muscle and bone, low activity in prostate and skin. Downstream anabolic effects without the full androgenic profile of AAS.
Pharmacokinetics
Plasma half-life approximately 24 hours. Once-daily dosing sufficient. Steady-state in 5 days.
Cycle & Stacking Guide
Beginner SARM cycle: 10–15 mg/day × 8 weeks. Mild mini-PCT (Nolva 20 mg/day × 4 weeks) if bloodwork confirms suppression. Stacks with cardarine for recomp or with TRT for lean gains.
Manufacturer Notes
Elbrus Pharmaceuticals is an Eastern European producer with GMP certification. Their pharmacology catalogue is broad, covering AAS, peptides, and harm-reduction supports.
Storage & Handling
Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.